$86 Million is the total value of Foresite Capital Management III, LLC's 8 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 0.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
FGEN | Buy | FibroGen, Inc. | $11,342,000 | +59.9% | 305,784 | +77.3% | 13.18% | +149.6% |
ACRS | Buy | Aclaris Therapeutics, Inc. | $10,483,000 | +495.6% | 1,620,244 | +136.6% | 12.18% | +830.2% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-16
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
Epizyme, Inc. | 24 | Q3 2021 | 17.6% |
Acceleron Pharma Inc. | 22 | Q3 2021 | 25.9% |
CymaBay Therapeutics, Inc. | 20 | Q3 2022 | 17.6% |
Aerie Pharmaceuticals, Inc. | 18 | Q1 2020 | 33.5% |
Ascendis Pharma A/S | 17 | Q3 2022 | 47.8% |
Alder BioPharmaceuticals, Inc. | 16 | Q3 2019 | 27.4% |
Natera, Inc. | 16 | Q3 2022 | 21.5% |
Aimmune Therapeutics, Inc. | 16 | Q3 2019 | 8.1% |
Verona Pharma PLC. | 15 | Q3 2022 | 30.0% |
WAVE Life Sciences Ltd. | 15 | Q2 2019 | 20.0% |
View Foresite Capital Management III, LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2022-11-14 |
13F-HR | 2022-08-12 |
13F-HR | 2022-05-13 |
13F-HR | 2022-02-11 |
13F-HR | 2021-11-12 |
4 | 2021-11-03 |
13F-HR | 2021-08-16 |
13F-HR | 2021-05-17 |
13F-HR | 2021-02-16 |
3 | 2021-02-10 |
View Foresite Capital Management III, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.